Veloxis Pharmaceuticals has agreed to pay $46 million to resolve allegations of illegal kickbacks related to the promotion of its drug, Envarsus XR, used for transplant patients. The company was accused of providing financial incentives to doctors and healthcare providers to encourage them to prescribe their medication, violating the False Claims Act. The settlement follows an investigation by the Department of Justice, which found that Veloxis’s practices could have led to unnecessary costs billed to government healthcare programs. In addition to the financial settlement, Veloxis is implementing new compliance measures aimed at ensuring adherence to legal and ethical standards in their marketing practices. This case highlights the ongoing scrutiny of pharmaceutical companies regarding their marketing strategies and the importance of maintaining integrity in prescription practices to protect patients and healthcare systems.
For more details and the full reference, visit the source link below:
Read the complete article here: https://www.stl.news/veloxis-to-pay-46m-in-kickback-case/